Biogen (BIIB) Stock Upgrade Due to Pipeline Outlook
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowNeedham has upgraded Biogen (BIIB) due to optimism surrounding its pipeline. While specific figures related to the target price or P/E ratios were not disclosed, upgrades can indicate potential growth in stock value and investor confidence. This action is significant as it may lead to increased trading volume and interest in Biogen shares. Market responses to upgrades often correlate positively with future price movements.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Biogen Inc. (BIIB)
Biogen is a biotech focused on neurological diseases.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BIIB news
- Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
- Premarket Stocks: Versant, Biogen, Cisco Moves and Impacts
- Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
- Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition
- Biogen (BIIB) to Acquire Apellis for $5.6 Billion
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
